Post by PharmaShots

Gilead Sciences’ sNDA for once-weekly oral Yeztugo accepted by the FDA for HIV PrEP, building on lenacapavir’s high efficacy in the PURPOSE 1 and PURPOSE 2 trials and potentially becoming the first long-acting oral PrEP option if approved Subscribe to our weekly newsletter and never miss a beat: https://lnkd.in/gTU62Zbz #gilead #yeztugo #snda #usfda #hiv #prep #lenacapavir #purpose1 #purpose2 #regulatory #phaseiii #truvada https://lnkd.in/gtVCS-v3